000136398 001__ 136398
000136398 005__ 20240826132401.0
000136398 0247_ $$2doi$$a10.7717/peerj.11260
000136398 0248_ $$2sideral$$a126639
000136398 037__ $$aART-2021-126639
000136398 041__ $$aeng
000136398 100__ $$aAndrés-Esteban E.M.
000136398 245__ $$aOutcomes of hospitalized patients with COVID-19 according to level of frailty
000136398 260__ $$c2021
000136398 5060_ $$aAccess copy available to the general public$$fUnrestricted
000136398 5203_ $$aBackground: The complications from coronavirus disease 2019 (COVID-19) have been the subject of study in diverse scientific reports. However, many aspects that influence the prognosis of the disease are still unknown, such as frailty, which inherently reduces resistance to disease and makes people more vulnerable. This study aimed to explore the complications of COVID-19 in patients admitted to a third-level hospital and to evaluate the relationship between these complications and frailty.
Methods: An observational, descriptive, prospective study was performed in 2020. A sample of 254 patients from a database of 3, 112 patients admitted to a high-level hospital in Madrid, Spain was analyzed. To assess frailty (independent variable) the Clinical Frailty Scale (CFS) was used. The outcome variables were sociodemographic and clinical, which included complications, length of stay, intensive care unit (ICU) admission and prognosis.
Results: A total of 13.39% of the patients were pre-frail and 17.32% were frail. Frail individuals had a shorter hospital stay, less ICU admission, higher mortality and delirium, with statistical significance.
Conclusion: Frailty assessment is a crucial approach in patients with COVID-19, given a higher mortality rate has been demonstrated amongst frail patients. The CFS could be a predictor of mortality in COVID-19.
000136398 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/COV20-00519$$9info:eu-repo/grantAgreement/ES/ISCIII/COV20-00634
000136398 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000136398 590__ $$a3.061$$b2021
000136398 591__ $$aMULTIDISCIPLINARY SCIENCES$$b33 / 74 = 0.446$$c2021$$dQ2$$eT2
000136398 592__ $$a0.766$$b2021
000136398 593__ $$aAgricultural and Biological Sciences (miscellaneous)$$c2021$$dQ1
000136398 593__ $$aNeuroscience (miscellaneous)$$c2021$$dQ1
000136398 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2021$$dQ1
000136398 594__ $$a4.7$$b2021
000136398 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000136398 700__ $$aQuintana-Diaz M.
000136398 700__ $$aRamírez-Cervantes K.L.
000136398 700__ $$aBenayas-Peña I.
000136398 700__ $$aSilva-Obregón A.
000136398 700__ $$0(orcid)0000-0002-5494-6550$$aMagallón-Botaya R.$$uUniversidad de Zaragoza
000136398 700__ $$aSantolalla-Arnedo I.
000136398 700__ $$aJuárez-Vela R.
000136398 700__ $$aGea-Caballero V.
000136398 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000136398 773__ $$g9 (2021), e11260 [18 pp.]$$pPeerJ$$tPeerJ$$x2167-8359
000136398 8564_ $$s2183717$$uhttps://zaguan.unizar.es/record/136398/files/texto_completo.pdf$$yVersión publicada
000136398 8564_ $$s2343179$$uhttps://zaguan.unizar.es/record/136398/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000136398 909CO $$ooai:zaguan.unizar.es:136398$$particulos$$pdriver
000136398 951__ $$a2024-08-22-13:17:21
000136398 980__ $$aARTICLE